lesinurad 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5075 878672-00-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lesinurad
  • zurampic
  • RDEA594 Sodium
  • RDEA594
Lesinurad reduces serum uric acid levels by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. Lesinurad inhibited the function of two apical transporters responsible for uric acid reabsorption, uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4), with IC50 values of 7.3 and 3.7 μM, respectively. URAT1 is responsible for the majority of the reabsorption of filtered uric acid from the renal tubular lumen. OAT4 is a uric acid transporter associated with diuretic-induced hyperuricemia.
  • Molecular weight: 404.28
  • Formula: C17H14BrN3O2S
  • CLOGP: 4.01
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 68.01
  • ALOGS: -4.72
  • ROTB: 4

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.29 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.43 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 18, 2016 EMA AstraZeneca AB
Dec. 22, 2015 FDA ARDEA BIOSCIENCES INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M04AB05 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations increasing uric acid excretion
MeSH PA D018501 Antirheumatic Agents
MeSH PA D006074 Gout Suppressants
MeSH PA D014528 Uricosuric Agents
FDA MoA N0000190118 Cytochrome P450 3A Inducers
FDA MoA N0000192340 Urate Transporter 1 Inhibitors
FDA EPC N0000192341 Urate Transporter 1 Inhibitor
CHEBI has role CHEBI:35841 uricosuric drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperuricemia indication 35885006 DOID:1920




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.5 acidic
pKa2 1.05 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 10183012 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8283369 Nov. 26, 2028 ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8283369 Nov. 26, 2028 TREATMENT OF GOUT
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 10183012 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8283369 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 10183012 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8283369 Nov. 26, 2028 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8546437 April 29, 2029 TREATMENT OF HYPERURICEMIA
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8546437 April 29, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8546437 April 29, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8084483 Aug. 17, 2029 REDUCTION OF SERUM URIC ACID LEVELS
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8084483 Aug. 17, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8084483 Aug. 17, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8357713 Dec. 22, 2029 REDUCTION OF SERUM URIC ACID LEVELS
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8357713 Dec. 22, 2029 TREATMENT OF GOUT
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 8357713 Dec. 22, 2029 TREATMENT OF HYPERURICEMIA
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8357713 Dec. 22, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 8357713 Dec. 22, 2029 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 9216179 Aug. 1, 2031 COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 9216179 Aug. 1, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 9216179 Aug. 1, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
200MG ZURAMPIC IRONWOOD PHARMS INC N207988 Dec. 22, 2015 DISCN TABLET ORAL 9956205 Dec. 28, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
200MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 9956205 Dec. 28, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
300MG;200MG DUZALLO IRONWOOD PHARMS INC N209203 Aug. 18, 2017 DISCN TABLET ORAL 9956205 Dec. 28, 2031 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 22 member 12 Transporter INHIBITOR IC50 5.14 DRUG LABEL DRUG LABEL
Solute carrier family 22 member 11 Transporter INHIBITOR IC50 5.43 DRUG LABEL

External reference:

IDSource
D09921 KEGG_DRUG
4036022 VANDF
CHEBI:90929 CHEBI
CHEMBL2105720 ChEMBL_ID
C000593471 MESH_SUPPLEMENTAL_RECORD_UI
7673 IUPHAR_LIGAND_ID
9345 INN_ID
DB11560 DRUGBANK_ID
09ERP08I3W UNII
53465279 PUBCHEM_CID
1731031 RXNORM
237601 MMSL
31385 MMSL
d08406 MMSL
715259003 SNOMEDCT_US
715745009 SNOMEDCT_US
C3886073 UMLSCUI
CHEMBL2105716 ChEMBL_ID
016642 NDDF

Pharmaceutical products:

None